Live Feeds
● LIVE Updated 57m ago · 12 sources tracked

Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Eli Lilly reported that its daily oral weight-loss drug Foundayo met its main goal in a late-stage clinical trial involving adults with obesity and obstructive sleep apnea. The Phase 3 ATTAIN-OSA study demonstrated that the daily GLP-1 pill significantly reduced obstructive sleep apnea severity, pointing to health benefits beyond weight loss. The pharmaceutical company intends to submit the data for FDA review and pursue a wider global rollout for sleep apnea treatment in this population. Analysts suggest the positive results could open a multi-billion-dollar market for the oral treatment.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Eli Lilly announced that its oral weight-loss drug Foundayo met Phase 3 ATTAIN-OSA trial goals in adults with obesity and obstructive sleep apnea.
  • ✓ The Phase 3 trial showed that Lilly's Foundayo, also known as orforglipron, significantly reduced obstructive sleep apnea severity.
  • ✓ The pharmaceutical group plans to submit Foundayo for FDA review and pursue a wider global rollout for sleep apnea treatment.
🛡️ Source Corroboration: 12 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly released Phase 3 clinical trial results showing its oral weight-loss drug Foundayo significantly improves obstructive sleep apnea severity.

Live updates

  1. Eli Lilly Says Foundayo Pill Eases Sleep Apnea in Late-Stage Trial

    Eli Lilly reported that its daily oral weight-loss drug Foundayo met its main goal in a late-stage clinical trial involving adults with obesity and obstructive sleep apnea. The Phase 3 ATTAIN-OSA study demonstrated that the daily GLP-1 pill significantly reduced obstructive sleep apnea severity, pointing to health benefits beyond weight loss. The pharmaceutical company intends to submit the data for FDA review and pursue a wider global rollout for sleep apnea treatment in this population. Analysts suggest the positive results could open a multi-billion-dollar market for the oral treatment.

    Why it matters

    Obstructive sleep apnea severely impacts health for many patients suffering from obesity, creating a high demand for effective non-surgical therapies. Drug developers are increasingly testing GLP-1 receptor agonists not just for weight management, but for comorbid conditions like sleep apnea and arthritis. Positive Phase 3 results strengthen Eli Lilly's market position against competitors as it prepares regulatory filings.

    What is confirmed

    • Eli Lilly announced that its oral weight-loss drug Foundayo met Phase 3 ATTAIN-OSA trial goals in adults with obesity and obstructive sleep apnea.
    • The Phase 3 trial showed that Lilly's Foundayo, also known as orforglipron, significantly reduced obstructive sleep apnea severity.
    • The pharmaceutical group plans to submit Foundayo for FDA review and pursue a wider global rollout for sleep apnea treatment.

    Still unconfirmed

    • Foundayo may unlock a new $23 billion market for Eli Lilly's GLP-1 pill portfolio.

    What to watch next

    • Official submission of Foundayo data to the FDA for review
    • Global regulatory filings for sleep apnea treatment indications
    Sources used for this update (13)
    1. CNBC — Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
    2. Reuters — Lilly's weight-loss pill meets main goal in late-stage sleep apnea study
    3. Bloomberg.com — Lilly’s Obesity Pill Foundayo Helps Control Sleep Apnea in Study
    4. Quartz — Eli Lilly's obesity pill showed it can ease sleep apnea in a late-stage trial
    5. Fierce Pharma — Lilly looks to gird Foundayo label after late-stage win in sleep apnea
    6. Yahoo Finance — AHA26: Lilly’s Foundayo benefits beyond weight loss in Phase III sleep apnoea win
    7. Seeking Alpha — Eli Lilly releases Foundayo sleep apnea data
    8. Scientific American — New clinical trial shows daily GLP-1 pill significantly improves sleep apnea
    9. Yahoo Finance — Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill
    10. Time Magazine — Weight-Loss Drugs May Help Sleep Apnea and Arthritis
    11. Eli Lilly — Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
    12. STAT — Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community